VSTM - Verastem, Inc.
| Previous Close | 5.33 |
| Open | 5.36 |
| Bid | 0.00 x 45900 |
| Ask | 0.00 x 1300 |
| Day's Range | 5.35 - 5.80 |
| 52 Week Range | 1.92 - 5.80 |
| Volume | 2,507,482 |
| Avg. Volume | 1,100,869 |
| Market Cap | 372.938M |
| Beta | 3.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.76 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.67 |
- Business Wire•yesterday
Verastem Oncology Announces Closing of Underwriter’s Option to Purchase Additional Shares
Verastem, Inc., (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has issued 1,166,666 shares of the Company’s common stock at a price to the public of $4.50 per share, pursuant to the full exercise of the underwriter’s option to purchase additional shares of common stock in connection with the Company’s previously announced public offering. The aggregate gross proceeds to Verastem Oncology from the offering, including the full exercise of the underwriter’s option, are expected to be $40.2 million.
- Business Wire•3 days ago
Verastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at the 3rd Annual Advances in Immuno-Oncology Congress
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that Jonathan Pachter, PhD, the Company’s Chief Scientific Officer, will give an oral presentation and moderate a roundtable discussion at the 3rd Annual Advances in Immuno-Oncology Congress being held May 24-25, 2018 in London, UK.
- Business Wire•8 days ago
Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting
Verastem Oncology , a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the selection of four abstracts for oral and poster presentations at the 23rd Congress of the European Hematology Association being held June 14-17, 2018 in Stockholm, Sweden.
- Business Wire•8 days ago
Verastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that five abstracts have been selected for poster presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 1-5, 2018 in Chicago. The Company will present data on its lead product candidate, duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, as well as defactinib, its oral small molecule inhibitor of Focal Adhesion Kinase (FAK). The poster presentations will highlight the latest findings from the Company’s ongoing clinical trials for duvelisib, the Phase 3 DUO study crossover extension in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), in addition to a Phase 1 study of defactinib in combination with pembrolizumab and gemcitabine in patients with relapsed/refractory pancreatic cancer.
- Motley Fool•9 days ago
Why Verastem Stock Is Plunging Today
The biotech is raising cash ahead of a potential launch of its first drug.
- Business Wire•9 days ago
Verastem Oncology Announces Pricing of Public Offering of Common Stock
Verastem, Inc., (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its registered underwritten public offering of 7,777,778 shares of its common stock at a price to the public of $4.50 per share. The gross proceeds to Verastem Oncology from the offering are expected to be $35 million. In addition, Verastem Oncology has granted the underwriter a 30-day option to purchase up to an additional 1,166,666 shares of its common stock.
- Benzinga•9 days ago
Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 15) Inspire Medical Systems Inc (NYSE: INSP ) Aptevo Therapeutics ...
- Business Wire•9 days ago
Verastem Oncology Announces Public Offering of Common Stock
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has commenced a registered underwritten public offering of $35 million of its shares of common stock. In addition, Verastem Oncology has granted the underwriter a 30-day option to purchase up to an additional $5.25 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Verastem Oncology.
- Business Wire•20 days ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to ten new employees to purchase an aggregate of 209,000 shares of Verastem Oncology’s common stock. The options were granted as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $4.19, the closing price of Verastem's common stock as reported by Nasdaq on May 1, 2018.
- Associated Press•21 days ago
Verastem: 1Q Earnings Snapshot
The Needham, Massachusetts-based company said it had a loss of 41 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Business Wire•21 days ago
Verastem Oncology Reports First Quarter 2018 Financial Results
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the quarter ended March 31, 2018 and provided an overview of certain corporate developments.
- Business Wire•22 days ago
Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, yes
- American City Business Journals•23 days ago
Boston biotech entrepreneur Christoph Westphal launches new startup
Westphal has a long track record of co-founding successful drug developers, including Alnylam Pharmaceuticals and Momenta Pharmaceuticals.
- Business Wire•last month
Verastem to Host Analyst and Investor Day on May 2, 2018
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it will host an Analyst and Investor Day titled, “Duvelisib: Harnessing the Power of Dual PI3K Inhibition,” on Wednesday, May 2, 2018 from 10:30 am – 1:00 pm ET in New York City.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•last month
Verastem (VSTM) in Focus: Stock Moves 8% Higher
Shares of Verastem (VSTM) rose nearly 8% yesterday.
- Business Wire•last month
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an aggregate of 364,000 shares of Verastem’s common stock.
- CNBC•2 months ago
Biotech shares soar on dealmaking, drug breakthroughs; AveXis jumps 77 percent
AveXis shares led the biotech sector higher on Monday after Novartis announced its plans to buy the gene therapy company.
- Benzinga•2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Verastem Inc (NASDAQ: VSTM ) stock gained more than ...
- Business Wire•2 months ago
FDA Accepts New Drug Application for Duvelisib and Grants Priority Review
Verastem, Inc. , a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S.
- Business Wire•2 months ago
Verastem to Present at the H.C. Wainwright Global Life Sciences Conference
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C.
- Zacks•2 months ago
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.
- Business Wire•2 months ago
Verastem Updates Presentation Time for Oppenheimer & Co. Healthcare Conference
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 28th Annual Oppenheimer & Co.
- Business Wire•2 months ago
Verastem to Present at Upcoming Conferences
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will
- Business Wire•2 months ago
Verastem Reports Year-End 2017 Financial Results
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the year ended December 31, 2017 and provided an overview of certain corporate developments and plans.
